Skip to main content
  • Information for
    • Students
    • Alumni & Friends
    • Faculty
    • Staff
    • Community
  • QUICK LINKS
  • DIRECTORY
  • APPLY
  • GIVE
  • RENT
Hunter College
About
  • Overview
  • Mission
  • Strategic Plan
  • Accreditation
  • Fast Facts
  • Office of the President
  • Capital Projects & Planning
  • Sustainability
  • Campus Information
  • Contact Us
Academics
  • Approach
  • Provost
  • Schools
  • Departments & Programs
  • Majors
  • Honors & Scholars
  • Education Abroad
  • Advising
  • Research & Creative Works
  • Course Catalogs
Admissions
  • Overview
  • Undergraduate
  • Graduate
  • Course Catalogs
Student Life
  • Clubs & Organizations
  • Residence Life
  • Athletics
  • Dining On Campus
  • Community
  • Events
  • News
  • Libraries
Hunter College Schools
  • School of Arts & Sciences
  • School of Education
  • School of Health Professions
  • Hunter-Bellevue School of Nursing
  • Silberman School of Social Work
More Schools
  • Hunter College Campus Schools
  • Hunter College Continuing Education
  • Libraries
  • Students
  • Alumni & Friends
  • Faculty
  • Staff
  • Community
  • Events
  • News
  • APPLY
  • GIVE
  • RENT
  • QUICK LINKS
  • DIRECTORY
SPEECH Conference
  • May 12 Agenda
  • Speakers
  • Research
  • Poster Sessions
  • Program Steering Committee

Chidiebere U. Awah

Chidiebere U Awah poster session
Engineered Destabilized AU Rich Elements on the 3’UTR of HER2 Degrades HER2, Inhibits Proliferation, and Induces Apoptosis in HER2+ Trastuzumab Resistant Breast Cancer Cells

Name Chidiebere U. Awah
Institution Hunter College, City University of New York
Research Field Basic Research
Role at Institution Post-Doctoral Fellow
Presenter(s) Chidiebere U. Awah

Abstract

Engineered Destabilized AU Rich Elements on the 3’UTR of HER2 Degrades HER2, Inhibits Proliferation, and Induces Apoptosis in HER2+ Trastuzumab Resistant Breast Cancer Cells

Chidiebere U. Awah1,2,  Yana Glemaud1, Fayola Levine1,3, Leonard Ash1, Afrin Ansary1, Olorunseun Ogunwobi1,2,3.

1Department of Biological Sciences, Hunter College of The City University of New York.
2Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York.
3Hunter College for Cancer Health Disparities Research, Hunter College of The City University of New York.

Resistance to molecular targeted therapy is a major challenge facing breast cancer patients and unfavorably impacts clinical outcomes, leading to hundreds of thousands of deaths yearly. Resistance to cancer therapies arises from many factors. One of the key factors driving resistance is oncogenes which initiate pro-growth, pro-survival and metastatic programs that enable cancers escape various therapies. In HER2+ breast cancer, the oncogene HER2 is the master driver of this tumor. Trastuzumab effectively targets HER2. While this is generally successful, some patients who have HER2+ breast cancer develop resistance to trastuzumab and there are limited treatment options for them. Moreover, for low HER2+ expressing breast cancer, there are limited treatment options for them. And in African American women who have HER2+ breast cancer, there is disparity in their treatment outcomes. We have discovered that 3’UTR of HER2 is enriched with poly U stabilizing AU rich elements (ARE). We have developed a novel technology wherein we engineered the stabilizing HER2 3’UTR ARE motifs to destabilizing motif in HER2+ and HER2+ trastuzumab resistant breast cancer cells to control HER2 transcript. We achieved complete degradation of HER2 within 4-8 days in HER2+ wildtype breast cancer cells and 9-11 days in HER2+ trastuzumab resistant breast cancer cells. We had loss of cancer cell viability by more than 90%. We also show that control of HER2 transcript downregulated HER2-dependent kinases, transcription factors, and HER2 interactome. Mechanistically, the control of HER2 transcript was achieved by destabilized ARE sequence specificity which triggered the proteins PARN, XRN1 and CNOT1 to degrade HER2 transcript and this led to induction of active caspase 3/7, reduction of cell size, and severe distortion and disruption of the cancer cell membrane leading to cell death. Taken together, we have developed a novel approach to control HER2 transcript expression both on spatial and temporal scale. This novel approach offers applications for targeting HER2+ trastuzumab resistant breast cancer as well as other cancers resistant to HER2 targeted therapy and driven by pervasive oncogenic signals.

HUNTER

Hunter College
695 Park Ave NY, NY 10065
(212) 772-4000

  • Facebook
  • Twitter
  • Instagram
  • Flickr
  • ABOUT
  • ACADEMICS
  • ADMISSIONS
  • EVENTS
  • NEWS
Hunter College Schools
  • School of Arts & Sciences
  • School of Education
  • School of Health Professions
  • Hunter-Bellevue School of Nursing
  • Silberman School of Social Work
  • School of Arts & Sciences
  • School of Education
  • School of Health Professions
  • Hunter-Bellevue School of Nursing
  • Silberman School of Social Work
Our Other Schools
  • Hunter College Campus Schools
  • Hunter College Continuing Education
  • Hunter College Campus Schools
  • Hunter College Continuing Education
Hunter College Libraries
More Info
  • Bookstore
  • Contact Us & Feedback
  • Jobs
  • Public Safety
  • Roosevelt House
  • Student Housing
  • Space Rentals
  • Bookstore
  • Contact Us & Feedback
  • Jobs
  • Public Safety
  • Roosevelt House
  • Student Housing
  • Space Rentals
Public Information
  • Annual Security & Fire Safety Report
  • Consumer Information
  • CUNY Tobacco Policy
  • Enough is Enough
  • Focus on Campus
  • Annual Security & Fire Safety Report
  • Consumer Information
  • CUNY Tobacco Policy
  • Enough is Enough
  • Focus on Campus
CUNY
  • © 2025 Hunter College
  • Accessibility
  • Privacy
  • Terms